With mounting competition in Her2-directed breast cancer treatment, Zymeworks’ latecomer struggles to show that it’s better.
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Merck's move on a target that has attracted little attention – Liv-1 – means future data readouts are now eagerly awaited.
As Immunomedics and Seattle both get backing from the big boys, antibody-drug conjugates finally come of age.
The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.